在竞争风险背景下对动静脉瘘疗效的前瞻性分析。

IF 3.2 Q1 UROLOGY & NEPHROLOGY Kidney360 Pub Date : 2024-11-19 DOI:10.34067/KID.0000000650
Anukul Ghimire, Anita M Lloyd, Susan Szigety, Jose Luis Merino, Karim Alibhai, Gerrit Winkelaar, Robert R Quinn, Marcello Tonelli
{"title":"在竞争风险背景下对动静脉瘘疗效的前瞻性分析。","authors":"Anukul Ghimire, Anita M Lloyd, Susan Szigety, Jose Luis Merino, Karim Alibhai, Gerrit Winkelaar, Robert R Quinn, Marcello Tonelli","doi":"10.34067/KID.0000000650","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Many patients with newly created arteriovenous fistulas (AVF) may die before the AVF is needed for hemodialysis. However, formal competing risks frameworks are rarely used to report AVF patency, which may lead to biased estimates. We sought to identify the proportion of newly created AVF experiencing primary non-function and to describe long-term patency using a competing risk framework.</p><p><strong>Methods: </strong>We did a prospective observational study in 257 adults with newly created AVF in Alberta, Canada. The primary outcome was primary non-function. Secondary outcomes included loss of primary-patency, loss of assisted primary-patency, and loss of secondary functional-patency. Results were presented using icon-array plots to form the basis for future decision aids.</p><p><strong>Results: </strong>Participants were 63.0% male with mean age 62.3 years and median follow-up of 18.5 months (range 0.02-180 months). Of 257 participants, 50 could not be assessed for function or primary non-function, usually due to death. Of the remaining 207, 102 (49.3%) had primary non-function, and function was ultimately established for 142 (68.6%). Thus, only 142 of the 257 participants (55.3%) ultimately used the AVF for hemodialysis. High rates of competing risks led to biased results from Kaplan-Meier analyses of lost patency. When accounting for competing risks, loss of primary-patency among AVF with established function was 36.6%, 65.5% and 66.2%, at 1y, 3y and 5y respectively.</p><p><strong>Conclusions: </strong>Only 55% of fistulas were ultimately used for hemodialysis when accounting for competing risks and primary non-function. These results and the icon-array plots may inform discussions surrounding vascular access options for patients.</p>","PeriodicalId":17882,"journal":{"name":"Kidney360","volume":" ","pages":""},"PeriodicalIF":3.2000,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Prospective Analysis of Arteriovenous Fistula Performance in the Context of Competing Risks.\",\"authors\":\"Anukul Ghimire, Anita M Lloyd, Susan Szigety, Jose Luis Merino, Karim Alibhai, Gerrit Winkelaar, Robert R Quinn, Marcello Tonelli\",\"doi\":\"10.34067/KID.0000000650\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Many patients with newly created arteriovenous fistulas (AVF) may die before the AVF is needed for hemodialysis. However, formal competing risks frameworks are rarely used to report AVF patency, which may lead to biased estimates. We sought to identify the proportion of newly created AVF experiencing primary non-function and to describe long-term patency using a competing risk framework.</p><p><strong>Methods: </strong>We did a prospective observational study in 257 adults with newly created AVF in Alberta, Canada. The primary outcome was primary non-function. Secondary outcomes included loss of primary-patency, loss of assisted primary-patency, and loss of secondary functional-patency. Results were presented using icon-array plots to form the basis for future decision aids.</p><p><strong>Results: </strong>Participants were 63.0% male with mean age 62.3 years and median follow-up of 18.5 months (range 0.02-180 months). Of 257 participants, 50 could not be assessed for function or primary non-function, usually due to death. Of the remaining 207, 102 (49.3%) had primary non-function, and function was ultimately established for 142 (68.6%). Thus, only 142 of the 257 participants (55.3%) ultimately used the AVF for hemodialysis. High rates of competing risks led to biased results from Kaplan-Meier analyses of lost patency. When accounting for competing risks, loss of primary-patency among AVF with established function was 36.6%, 65.5% and 66.2%, at 1y, 3y and 5y respectively.</p><p><strong>Conclusions: </strong>Only 55% of fistulas were ultimately used for hemodialysis when accounting for competing risks and primary non-function. These results and the icon-array plots may inform discussions surrounding vascular access options for patients.</p>\",\"PeriodicalId\":17882,\"journal\":{\"name\":\"Kidney360\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2024-11-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Kidney360\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.34067/KID.0000000650\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Kidney360","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.34067/KID.0000000650","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:许多新造动静脉瘘(AVF)患者可能会在血液透析需要动静脉瘘之前死亡。然而,正式的竞争风险框架很少被用于报告动静脉瘘的通畅情况,这可能会导致估计值出现偏差。我们试图确定新建立的动静脉瘘中出现原发性无功能的比例,并使用竞争风险框架描述长期通畅情况:我们在加拿大艾伯塔省对 257 名患有新造动静脉瘘的成人进行了前瞻性观察研究。主要结果是原发性无功能。次要结果包括原发性瓣膜丧失、辅助性原发性瓣膜丧失和继发性功能性瓣膜丧失。研究结果通过图标阵列图呈现,为未来的决策辅助工具奠定基础:63.0%的参与者为男性,平均年龄为 62.3 岁,中位随访时间为 18.5 个月(0.02-180 个月)。在 257 名参与者中,有 50 人无法进行功能或主要无功能评估,通常是因为死亡。在剩余的 207 名参与者中,102 人(49.3%)有原发性无功能,142 人(68.6%)最终确定了功能。因此,在 257 名参与者中,只有 142 人(55.3%)最终使用动静脉瘘进行血液透析。竞争风险的高发生率导致卡普兰-梅耶(Kaplan-Meier)失通分析的结果存在偏差。如果考虑到竞争风险,1年、3年和5年后,功能已确立的动静脉瘘的主要通畅性丧失率分别为36.6%、65.5%和66.2%:结论:考虑到竞争风险和原发性无功能,只有 55% 的瘘管最终用于血液透析。这些结果和图标阵列图可以为讨论患者的血管通路选择提供参考。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Prospective Analysis of Arteriovenous Fistula Performance in the Context of Competing Risks.

Background: Many patients with newly created arteriovenous fistulas (AVF) may die before the AVF is needed for hemodialysis. However, formal competing risks frameworks are rarely used to report AVF patency, which may lead to biased estimates. We sought to identify the proportion of newly created AVF experiencing primary non-function and to describe long-term patency using a competing risk framework.

Methods: We did a prospective observational study in 257 adults with newly created AVF in Alberta, Canada. The primary outcome was primary non-function. Secondary outcomes included loss of primary-patency, loss of assisted primary-patency, and loss of secondary functional-patency. Results were presented using icon-array plots to form the basis for future decision aids.

Results: Participants were 63.0% male with mean age 62.3 years and median follow-up of 18.5 months (range 0.02-180 months). Of 257 participants, 50 could not be assessed for function or primary non-function, usually due to death. Of the remaining 207, 102 (49.3%) had primary non-function, and function was ultimately established for 142 (68.6%). Thus, only 142 of the 257 participants (55.3%) ultimately used the AVF for hemodialysis. High rates of competing risks led to biased results from Kaplan-Meier analyses of lost patency. When accounting for competing risks, loss of primary-patency among AVF with established function was 36.6%, 65.5% and 66.2%, at 1y, 3y and 5y respectively.

Conclusions: Only 55% of fistulas were ultimately used for hemodialysis when accounting for competing risks and primary non-function. These results and the icon-array plots may inform discussions surrounding vascular access options for patients.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Kidney360
Kidney360 UROLOGY & NEPHROLOGY-
CiteScore
3.90
自引率
0.00%
发文量
0
期刊最新文献
Higher Serum Alkaline Phosphatase is Risk for Death and Fracture: A Nationwide Cohort Study of Japanese Dialysis Patients. Novel Biomarkers and Imaging Tests for AKI Diagnosis in Patients with Cancer. Association of Fibroblast Growth Factor 23 and Cardiac Mechanics in the Cardiovascular Health Study. Bridging Policy and Practice: Reforming Prior Authorization in Kidney Care. Facility-Level Variation in Nephrology Care among Veterans after Urinary Stone Diagnosis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1